- 4-Week # shares bought: 2,941
- 4-Week # shares sold: 8,000
- 12-Week # shares bought: 2,941
- 12-Week # shares sold: 90,283
- 24-Week # shares bought: 2,941
- 24-Week # shares sold: 105,283
The company received a thumbs up from an FDA advisory committee for its CAR-T therapy to treat leukemia in children and young adults.
bluebird bio appointed John O. Agwunobi, M.D. and Douglas A. Melton, Ph.D. to its Board of Directors.
Comey's testimony? U.K. elections? Eurozone news? These can be new buying opportunities, says Jim Cramer.